Pre-surgical oncolytic virotherapy improves breast cancer outcomes

Victor Mullins-Dansereau; Grégory Petrazzo; Karen Geoffroy; Delphine Béland; Marie-Claude Bourgeois-Daigneault

doi:10.1080/2162402X.2019.1655363

Pre-surgical oncolytic virotherapy improves breast cancer outcomes

Oncoimmunology. 2019 Aug 19;8(11):e1655363. doi: 10.1080/2162402X.2019.1655363. eCollection 2019.

Authors

Victor Mullins-Dansereau^{1

2

3}, Grégory Petrazzo^{1

2

3}, Karen Geoffroy^{1

2

3}, Delphine Béland^{1

2

3}, Marie-Claude Bourgeois-Daigneault^{1

2

3}

Affiliations

¹ Cancer axis, CRCHUM: "Centre Hospitalier de l'Université de Montréal" Research Centre, Montreal, Canada.
² "Institut du cancer de Montréal", Montreal, Canada.
³ Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montreal, Canada.

Abstract

Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration before surgery efficiently prevents relapse, controls metastases and sensitizes tumors to immune checkpoint inhibitors (ICIs).

Keywords: Oncolytic virotherapy; breast cancer; immune checkpoint blockade; neoadjuvant therapy; triple-negative breast cancer.

Publication types

Research Support, Non-U.S. Gov't

Grants and funding

This work was supported by the Institut du cancer de Montreal.